Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
NCT ID: NCT00262990
Last Updated: 2020-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
829 participants
INTERVENTIONAL
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patupilone
EPO906 (Patupilone)
doxorubicin
doxorubicin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EPO906 (Patupilone)
doxorubicin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Confirmed diagnosis of ovarian, fallopian or peritoneal cancer
* No more than three chemotherapy regimens
* Most recent regimen must have been platinum based
Exclusion Criteria
* Have had previous chemotherapy within 3 weeks
* Recovering from any surgery for any cause
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alaska Cancer Research & Education Center
Anchorage, Alaska, United States
Northern Arizona Hematology & Oncology Associates
Flagstaff, Arizona, United States
Mayo Center for Women's Health
Scottsdale, Arizona, United States
Northern Arizona Hematology & Oncology Associates
Sedona, Arizona, United States
Genesis Cancer Center
Hot Springs, Arkansas, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Yanagihara, Ronald H.
Gilroy, California, United States
California Cancer Care, Inc.
Greenbrae, California, United States
University of California - San Diego/ Moores Cancer Center
La Jolla, California, United States
LAC & USC Women's & Children's Hospital
Los Angeles, California, United States
Gynecologic Oncology associates
Newport Beach, California, United States
UC Davis Cancer Center
Sacramento, California, United States
California Pacific Medical Center Research Institute
San Francisco, California, United States
Anschutz Cancer Pavilion
Aurora, Colorado, United States
Anschutz Cancer Pavilion - Clinical Investigations Core
Aurora, Colorado, United States
University Of Colorado Health Sciences Center
Denver, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Christiana Gynecologic Oncology, LLC
Newark, Delaware, United States
Washington Hospital Center/Medstar Research Institute
Washington D.C., District of Columbia, United States
Florida Gynecologic Oncology
Fort Myers, Florida, United States
Miami Cancer Center at Mercy Hospital
Miami, Florida, United States
Miami Cancer Center at University Hospital
Miami, Florida, United States
University of Miami
Miami, Florida, United States
Mt. Sinai Medical Center
Miami, Florida, United States
Advanced Medical Specialties
Miami, Florida, United States
Ocala Oncology Center
Ocala, Florida, United States
MD Anderson Cancer Center of Orlando
Orlando, Florida, United States
Oncology & Hematology Associates of West Broward
Tamarac, Florida, United States
Xelero Medical Research/Giselle Ghurani
Tampa, Florida, United States
Medical College of Georgia
Augusta, Georgia, United States
Memorial Health University Medical Center
Savannah, Georgia, United States
Kapiolani Medical Center for Women and Children/Univ. of HI
Honolulu, Hawaii, United States
Northwest Memorial Hospital
Chicago, Illinois, United States
Rush University Medical Center
Chicago, Illinois, United States
Cancer Institute of Central Illinois/Decatur Memorial Hospital
Decatur, Illinois, United States
Indiana University Obstetrics
Indianapolis, Indiana, United States
Indiana University Cancer Center/Indiana UNiversity Melvin & Bren Simon Cancer Center
Indianapolis, Indiana, United States
Gynecologic Oncology of Indiana/St. Francis Cancer Research Foundation
Indianapolis, Indiana, United States
Northern Indiana Cancer Research Consortium
South Bend, Indiana, United States
Louisville Oncology
Louisville, Kentucky, United States
Franklin Square Hospital Center
Baltimore, Maryland, United States
Boston University Medical Center Hospital
Boston, Massachusetts, United States
Providence Cancer Center
Southfield, Michigan, United States
Minnesota Oncology/Hematology, PA
Burnsville, Minnesota, United States
St. Luke's Hospital
Duluth, Minnesota, United States
Minnesota Oncology/Hematology, PA
Edina, Minnesota, United States
Minnesota Oncology/Hematology Associates of Central Illinois
Minneapolis, Minnesota, United States
University of Minnesota
Minneapolis, Minnesota, United States
Metro-MN CCOP
Saint Louis Park, Minnesota, United States
Minnesota Oncology Hematology
Saint Paul, Minnesota, United States
The West Clinic
Corinth, Mississippi, United States
The West Clinic
Southaven, Mississippi, United States
St. Luke's Hospital of Kansas City/St. Luke's Cancer Institute
Kansas City, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Southeast Nebraska Oncology/Southeast Nebraska Cancer Center
Lincoln, Nebraska, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Women's Cancer Center of Nevada
Las Vegas, Nevada, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Hematology and Oncology Associates of Northern New Jersey
Morristown, New Jersey, United States
University of Medicine and Dentistry of New Jersey/The Cancer Institute of Neew Jersey
New Brunswick, New Jersey, United States
New York Oncology Hematology, P.C.
Albany, New York, United States
Schwartz Gynecologic Oncology, PLLC
Babylon, New York, United States
Bellview Hospital
New York, New York, United States
New York University School of Medicine/NYU Cancer Institute
New York, New York, United States
NYU Cancer Institute
New York, New York, United States
St. Vincent Catholic Medical Center of New York
Staten Island, New York, United States
Brody School of Medicine
Greenville, North Carolina, United States
New Hanover Regional Medical Center/Zimmer Cancer Center
Wilmington, North Carolina, United States
Ohio State University Medical Center
Columbus, Ohio, United States
Camelot Women's Cancer
Columbus, Ohio, United States
The Arthur G. James Cancer Hospital
Columbus, Ohio, United States
Cancer Care Associates
Tulsa, Oklahoma, United States
Oncology Associates of Oregon, PC/Willaimette Valley Cancer Center
Eugene, Oregon, United States
Northwest Cancer Specialists, P.C.
Portland, Oregon, United States
Willamette Valley Cancer Center
Springfield, Oregon, United States
Medical Oncology Associates of Wyoming Valley, PC
Kingston, Pennsylvania, United States
Magee - Women's Hospital
Pittsburgh, Pennsylvania, United States
GYN Oncology Research/Gynecologic Oncology Research & Development, LLC
Greenville, South Carolina, United States
Chattanooga GYN Oncology
Chattanooga, Tennessee, United States
Hall and Martin MDs, PC
Knoxville, Tennessee, United States
The West Clinic
Memphis, Tennessee, United States
West Clinic
Memphis, Tennessee, United States
Texas Oncology, P.A.
Austin, Texas, United States
Texas Oncology
Austin, Texas, United States
Texas Oncology, P.A.
Bedford, Texas, United States
Texas Oncology, P.A.
Dallas, Texas, United States
Sammons Cancer Center
Dallas, Texas, United States
Texas Oncology, P.A.
Dallas, Texas, United States
Texas Oncology, P.A.
Fort Worth, Texas, United States
Oncology Consultants P.A.
Houston, Texas, United States
Cancer Care Center of South Texas
San Antonio, Texas, United States
Waco Cancer Care & Research Center
Waco, Texas, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
Cancer Outreach Associates
Abingdon, Virginia, United States
Northern Virginia Pelvic Surgery Associates
Annandale, Virginia, United States
Virginia Oncology Associates
Newport News, Virginia, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Virginia Commonwealth University/VCU Massey Cancer Center
Richmond, Virginia, United States
Gersh, Robert
Spokane, Washington, United States
Northwest Cancer Specialists, P.C.
Vancouver, Washington, United States
Northwest Cancer Specialists
Vancouver, Washington, United States
Yakima Valley Memorial Hospital
Yakima, Washington, United States
Aurora Medical Gyn Group
West Allis, Wisconsin, United States
Novartis Investigative Site
Adelaide, , Australia
Novartis Investigative Site
Herston, , Australia
Novartis Investigative Site
Nedlands, WA, , Australia
Novartis Investigative Site
South Brisbane, , Australia
Novartis Investigative Site
St Leonards, , Australia
Novartis Investigative Site
Wodonga, , Australia
BC Cancer Agency
Vancouver, British Columbia, Canada
Novartis Investigative Site
Calgary, , Canada
Novartis Investigative Site
Montreal, , Canada
Novartis Investigative Site
North York, , Canada
Novartis Investigative Site
Québec, , Canada
Novartis Investigative Site
Sherbrooke, , Canada
Novartis Investigative Site
Toronto, , Canada
Novartis Investigative Site
Odense, , Denmark
Novartis Investigative Site
Vejle, , Denmark
Novartis Investigative Site
Helsinki, , Finland
Novartis Investigative Site
Kuopio, , Finland
Novartis Investigative Site
Tampere, , Finland
Novartis Investigative Site
Amboise, , France
Novartis Investigative Site
Bordeaux, , France
Novartis Investigative Site
Caen, , France
Novartis Investigative Site
Herblain Cedec, , France
Novartis Investigative Site
Villejuif, , France
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Bologna, , Italy
Novartis Investigative Site
Milan, , Italy
Novartis Investigative Site
Modena, , Italy
Novartis Investigative Site
Monza, , Italy
Novartis Investigative Site
Padua, , Italy
Novartis Investigative Site
Roma, , Italy
Novartis Investigative Site
Torino, , Italy
Novartis Investigative Site
Krakow, , Poland
Novartis Investigative Site
Cape Town, , South Africa
Novartis Investigative Site
Johannesburg, Gauteng, , South Africa
Novartis Investigative Site
Klerksdorp, , South Africa
Novartis Investigative Site
Port Elizabeth, , South Africa
Novartis Investigative Site
Pretoria, Gauteng, , South Africa
Novartis Investigative Site
Pretoria, Guateng, , South Africa
Novartis Investigative Site
Sandton, Gauteng, , South Africa
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Glasgow, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
Metropolitan Borough of Wirral, , United Kingdom
Novartis Investigative Site
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Newhouse R, Nelissen E, El-Shakankery KH, Rogozinska E, Bain E, Veiga S, Morrison J. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Database Syst Rev. 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3.
Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2012 Nov 1;30(31):3841-7. doi: 10.1200/JCO.2011.38.8082. Epub 2012 Sep 17.
Related Links
Access external resources that provide additional context or updates about the study.
In the search box enter NCT00262990
Select "Ovarian Cancer"
Results for CEPO906A2303 from the Novartis Clinical Trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEPO906A2303
Identifier Type: -
Identifier Source: org_study_id